[
    [
        {
            "time": "",
            "original_text": "健帆生物回复关注函：拟转增扩张股本具备合理性 关注函",
            "features": {
                "keywords": [
                    "健帆生物",
                    "回复",
                    "关注函",
                    "转增",
                    "扩张股本",
                    "合理性"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物回复关注函：拟转增扩张股本具备合理性 关注函",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]